Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting
Authors:
Open Access
- 23 January 2007
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 109 (10) , 4171-4173
Abstract
The increasing usage of rituximab in the management of non-Hodgkin lymphoma (NHL) has created huge logistical challenges with respect to the delivery of this time- and labor-intensive drug. To address these challenges, we developed and tested the feasibility of a 90-minute infusion schedule for rituximab (20% of the dose administered in the first 30 minutes, remaining 80% administered over 60 minutes). A safety analysis performed in 150 patients receiving rituximab with corticosteroid-containing chemotherapy and 56 patients receiving rituximab as maintenance therapy demonstrated that this schedule was well tolerated, with no grade 3 or 4 infusion reactions observed. In addition, no increase in minor reactions was noted. More than 1200 patients have been treated with this rapid rituximab infusion schedule in the province of British Columbia (BC), demonstrating its safety in the community setting. The adoption of this 90-minute schedule as standard practice has had a positive impact on resource utilization.Keywords
This publication has 12 references indexed in Scilit:
- Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood, 2006
- Rapid infusion of rituximab with or without steroid‐containing chemotherapy: 1‐yr experience in a single institutionEuropean Journal of Haematology, 2006
- Accelerated Delivery of Rituximab Is Safe on an Out-Patient Basis.Blood, 2005
- “One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management.Blood, 2005
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable ToxicityJournal of Clinical Oncology, 2001
- Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)Blood, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998